Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M. Younossi, Victor Ankoma‐Sey, Susanne Beckebaum et al.|The Lancet|2019Cited by 1.2k
Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver diseaseMaria Kjærgaard, Aleksander Krag, Katrine Prier Lindvig et al.|Journal of Hepatology|2023Cited by 213
Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 IndividualsMaria Kjærgaard, Maja Thiele, Katrine Prier Lindvig et al.|Clinical Gastroenterology and Hepatology|2023Cited by 54
Development, validation, and prognostic evaluation of LiverPRO for the prediction of significant liver fibrosis in primary care: a prospective cohort studyKatrine Prier Lindvig, Maja Thiele, Katrine Holtz Thorhauge et al.|The Lancet. Gastroenterology & hepatology|2024Cited by 35